Market Closed -
Nasdaq
04:00:00 2024-05-01 pm EDT
|
5-day change
|
1st Jan Change
|
1.4
USD
|
+0.72%
|
|
-2.78%
|
-38.86%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
88.79
|
179.9
|
260.5
|
52.39
|
53.87
|
49.96
|
-
|
-
|
Enterprise Value (EV)
1 |
88.79
|
179.9
|
260.5
|
52.39
|
53.87
|
49.96
|
49.96
|
49.96
|
P/E ratio
|
-2.46
x
|
-6.46
x
|
-4.15
x
|
-0.72
x
|
-0.72
x
|
-0.93
x
|
0.97
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
52
x
|
168
x
|
972
x
|
273
x
|
523
x
|
56.2
x
|
0.29
x
|
0.52
x
|
EV / Revenue
|
52
x
|
168
x
|
972
x
|
273
x
|
523
x
|
56.2
x
|
0.29
x
|
0.52
x
|
EV / EBITDA
|
-3.57
x
|
-7.75
x
|
-4.59
x
|
-0.9
x
|
-1.03
x
|
-1.12
x
|
-
|
-
|
EV / FCF
|
-
|
-
|
-9.9
x
|
-0.91
x
|
-1.13
x
|
-0.85
x
|
-2.31
x
|
1.67
x
|
FCF Yield
|
-
|
-
|
-10.1%
|
-110%
|
-88.3%
|
-117%
|
-43.3%
|
59.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
5,162
|
6,788
|
8,377
|
10,252
|
23,526
|
35,686
|
-
|
-
|
Reference price
2 |
17.20
|
26.50
|
31.10
|
5.110
|
2.290
|
1.400
|
1.400
|
1.400
|
Announcement Date
|
3/11/20
|
3/9/21
|
3/28/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.708
|
1.069
|
0.268
|
0.192
|
0.103
|
0.8885
|
171.8
|
95.6
|
EBITDA
1 |
-24.85
|
-23.2
|
-56.72
|
-58.33
|
-52.15
|
-44.6
|
-
|
-
|
EBIT
1 |
-24.85
|
-23.2
|
-56.72
|
-58.33
|
-52.15
|
-47.39
|
75.05
|
-
|
Operating Margin
|
-1,454.92%
|
-2,170.35%
|
-21,165.3%
|
-30,381.77%
|
-50,629.13%
|
-5,334.2%
|
43.69%
|
-
|
Earnings before Tax (EBT)
1 |
-24.71
|
-23.08
|
-56.67
|
-62.62
|
-51.85
|
-51.69
|
-7.4
|
-
|
Net income
1 |
-24.71
|
-23.08
|
-56.67
|
-62.62
|
-51.85
|
-51.69
|
61.02
|
-
|
Net margin
|
-1,446.96%
|
-2,159.12%
|
-21,145.52%
|
-32,616.67%
|
-50,336.89%
|
-5,817.95%
|
35.52%
|
-
|
EPS
2 |
-7.000
|
-4.100
|
-7.500
|
-7.090
|
-3.170
|
-1.498
|
1.440
|
-
|
Free Cash Flow
1 |
-
|
-
|
-26.31
|
-57.55
|
-47.59
|
-58.58
|
-21.65
|
29.84
|
FCF margin
|
-
|
-
|
-9,815.67%
|
-29,976.04%
|
-46,203.88%
|
-6,593.13%
|
-12.6%
|
31.22%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/9/21
|
3/28/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.029
|
0.016
|
0.052
|
0.018
|
0.048
|
0.074
|
0.035
|
0.031
|
0.031
|
0.006
|
0.01
|
0.01
|
0.05
|
0.01
|
0.7147
|
EBITDA
1 |
-11.28
|
-29.77
|
-
|
-14.16
|
-
|
-16.64
|
-18.08
|
-16.2
|
-
|
-10.17
|
-10.5
|
-10.7
|
-21.2
|
-11
|
-12.3
|
EBIT
1 |
-11.28
|
-29.77
|
-16.86
|
-14.16
|
-10.66
|
-16.64
|
-18.08
|
-16.2
|
-7.701
|
-10.17
|
-7.228
|
-7.282
|
-
|
-8.114
|
-8.969
|
Operating Margin
|
-38,889.66%
|
-186,062.5%
|
-32,425%
|
-78,688.89%
|
-22,216.67%
|
-22,491.89%
|
-51,665.71%
|
-52,241.94%
|
-24,841.94%
|
-169,483.33%
|
-72,285%
|
-72,825%
|
-
|
-81,145%
|
-1,254.98%
|
Earnings before Tax (EBT)
1 |
-11.26
|
-29.76
|
-16.85
|
-14.14
|
-10.61
|
-21.02
|
-10.47
|
-16.52
|
-5.724
|
-19.13
|
-8.252
|
-8.355
|
-20.7
|
-9.01
|
-10.01
|
Net income
1 |
-11.26
|
-29.76
|
-16.85
|
-14.14
|
-10.61
|
-21.02
|
-10.47
|
-16.52
|
-5.724
|
-19.13
|
-8.252
|
-8.355
|
-20.7
|
-9.01
|
-10.01
|
Net margin
|
-38,844.83%
|
-185,975%
|
-32,400%
|
-78,566.67%
|
-22,108.33%
|
-28,408.11%
|
-29,925.71%
|
-53,293.55%
|
-18,464.52%
|
-318,800%
|
-82,523.3%
|
-83,550%
|
-41,400%
|
-90,096.7%
|
-1,401.02%
|
EPS
2 |
-1.400
|
-3.900
|
-2.000
|
-1.600
|
-1.200
|
-6.610
|
-0.8900
|
-1.050
|
-0.2900
|
-1.100
|
-0.2733
|
-0.2733
|
-0.7300
|
-0.2833
|
-0.2967
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/28/22
|
5/12/22
|
8/12/22
|
11/8/22
|
3/31/23
|
5/15/23
|
8/14/23
|
11/13/23
|
3/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-26.3
|
-57.6
|
-47.6
|
-58.6
|
-21.7
|
29.8
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
1
|
1.1
|
2.23
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
112.55%
|
0.64%
|
2.34%
|
Announcement Date
|
3/11/20
|
3/9/21
|
3/28/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Average target price
17.25
USD Spread / Average Target +1,132.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.86% | 49.6M | | +0.67% | 42.19B | | +44.30% | 40.15B | | -6.20% | 28.31B | | +6.55% | 24.63B | | -21.66% | 18.2B | | +29.96% | 12.01B | | -1.57% | 11.76B | | +16.03% | 10.4B | | -4.80% | 9.94B |
Other Biotechnology & Medical Research
|